<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>http://api.elsevier.com/content/abstract/scopus_id/84912001027</prism:url><dc:identifier>SCOPUS_ID:84912001027</dc:identifier><eid>2-s2.0-84912001027</eid><prism:doi>10.1080/02603594.2014.890099</prism:doi><dc:title>Targeted Chemotherapy with Metal Complexes</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><citedby-count>0</citedby-count><prism:publicationName>Comments on Inorganic Chemistry</prism:publicationName><dc:publisher>
Taylor and Francis Inc.

325 Chestnut St, Suite 800
Philadelphia
PA 19106

</dc:publisher><source-id>25242</source-id><prism:issn>15489574</prism:issn><prism:volume>34</prism:volume><prism:startingPage>114</prism:startingPage><prism:endingPage>123</prism:endingPage><prism:pageRange>114-123</prism:pageRange><prism:coverDate>2014-01-01</prism:coverDate><dc:creator><author auid="55488551900" seq="1"><ce:initials>A.G.</ce:initials><ce:indexed-name>Weidmann A.G.</ce:indexed-name><ce:surname>Weidmann</ce:surname><ce:given-name>Alyson G.</ce:given-name><preferred-name>
<ce:initials>A.G.</ce:initials>
<ce:indexed-name>Weidmann A.</ce:indexed-name>
<ce:surname>Weidmann</ce:surname>
<ce:given-name>Alyson G.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/55488551900</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60031581" id="60031581"/></author></dc:creator><dc:description><abstract original="y" xml:lang="eng">
<publishercopyright>Â© 2014, Taylor &amp; Francis Group, LLC.</publishercopyright>
<ce:para>Classical chemotherapeutics, such as cisplatin and its analogues, have been highly successful in the clinic, yet improvements can certainly be made, given the significant side effects associated with the killing of healthy cells. Recent advances in the field of chemotherapy include the development of targeted anticancer agents, compounds that are directed towards a specific biomarker of cancer, with the hopes that such targeted therapies might have reduced side effects given their greater selectivity. Here we discuss several transition metal complexes that are tailored towards various biomolecules associated with cancer. Most notably, the success of rhodium metalloinsertors, which specifically bind to nucleic acid base mismatches in DNA, highlight the enormous potential of this exciting new strategy.</ce:para>
</abstract></dc:description><link href="http://api.elsevier.com/content/abstract/scopus_id/84912001027" rel="self"/><link href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84912001027&amp;origin=inward" rel="scopus"/><link href="http://api.elsevier.com/content/search/scopus?query=refeid%282-s2.0-84912001027%29" rel="cited-by"/></coredata><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60031581" id="60031581"><affilname>California Institute of Technology</affilname></affiliation><authors><author auid="55488551900" seq="1"><ce:initials>A.G.</ce:initials><ce:indexed-name>Weidmann A.G.</ce:indexed-name><ce:surname>Weidmann</ce:surname><ce:given-name>Alyson G.</ce:given-name><preferred-name>
<ce:initials>A.G.</ce:initials>
<ce:indexed-name>Weidmann A.</ce:indexed-name>
<ce:surname>Weidmann</ce:surname>
<ce:given-name>Alyson G.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/55488551900</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60031581" id="60031581"/></author><author auid="35339273000" seq="2"><ce:initials>A.C.</ce:initials><ce:indexed-name>Komor A.C.</ce:indexed-name><ce:surname>Komor</ce:surname><ce:given-name>Alexis C.</ce:given-name><preferred-name>
<ce:initials>A.C.</ce:initials>
<ce:indexed-name>Komor A.</ce:indexed-name>
<ce:surname>Komor</ce:surname>
<ce:given-name>Alexis C.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/35339273000</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60031581" id="60031581"/></author><author auid="7403157589" seq="3"><ce:initials>J.K.</ce:initials><ce:indexed-name>Barton J.K.</ce:indexed-name><ce:surname>Barton</ce:surname><ce:given-name>Jacqueline K.</ce:given-name><preferred-name>
<ce:initials>J.K.</ce:initials>
<ce:indexed-name>Barton J.</ce:indexed-name>
<ce:surname>Barton</ce:surname>
<ce:given-name>Jacqueline K.</ce:given-name>
</preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7403157589</author-url><affiliation href="http://api.elsevier.com/content/affiliation/affiliation_id/60031581" id="60031581"/></author></authors></abstracts-retrieval-response>
